The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | EMERALD-1: durvalumab, bevacizumab and TACE in unresectable HCC
Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, discusses the Phase III EMERALD-1 study (NCT03778957) of durvalumab and bevacizumab with TACE versus TACE alone in patients with unresectable hepatocellular carcinoma (uHCC). The study found that addition of immunotherapy significantly improved progression-free survival and time to progression compared to TACE alone. Although treatment-emergent hepatic events were higher in the combination therapy arm, these were mostly low-grade, indicating a favorable risk-benefit profile for this combination therapy. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Eisai; Ipsen; Roche
Consulting or Advisory Role – AstraZeneca; BMS; Eisai; MSD Oncology; Roche
Research Funding – Eisai; Ipsen
